STOCK TITAN
  1. Home
  2. News
  3. ONCY

Oncolytics Biotech, Inc. - ONCY STOCK NEWS

Welcome to our dedicated news page for Oncolytics Biotech (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncolytics Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncolytics Biotech's position in the market.

News
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Rhea-AI Summary
Oncolytics Biotech receives $5 million grant from PanCAN for pancreatic cancer research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
News
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
Rhea-AI Summary
Oncolytics Biotech® Inc. to participate in fireside chat at Cantor Global Healthcare Conference 2023 with CEO Dr. Matt Coffey. One-on-one investor meetings available. Webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
-
News
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Oncolytics Biotech CEO to participate in fireside chat at H.C. Wainwright conference on Sep 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
News
Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Oncolytics Biotech announces positive results from Phase 2 trial in breast cancer and inclusion in Precision Promise trial for pancreatic cancer. Financials show $24.4 million in cash and a successful $15 million public offering. Management to host conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
-
News
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
News
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences earnings
News
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Rhea-AI Summary
Oncolytics Biotech announced that pelareorep has been selected for inclusion in Precision Promise, an adaptive Phase 3 clinical trial for pancreatic cancer. The trial aims to evaluate the combination of pelareorep with a checkpoint inhibitor and chemotherapeutic agents. If successful, this study could support the approval of pelareorep as a treatment for first-line metastatic pancreatic cancer. The trial design is expected to reduce costs by 50% compared to traditional trials and accelerate the development process by up to two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
clinical trial
-
News
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
Rhea-AI Summary
Oncolytics Biotech announced positive results from a phase 2 trial in HR+/HER2- metastatic breast cancer. The combination of pelareorep-paclitaxel reduced the risk of disease progression by 71% compared to paclitaxel monotherapy. The confirmed overall response rate was 37.5% with pelareorep-paclitaxel, compared to 13.3% with paclitaxel monotherapy. The 12-month progression-free survival rate was 32.8% for pelareorep-paclitaxel, compared to 0% for paclitaxel monotherapy and pelareorep-paclitaxel-avelumab. The company's breast cancer program is now phase 3-ready. Data will be discussed in a key opinion leader webinar.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
clinical trial
-
News
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.98%
Tags
conferences
News
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.98%
Tags
clinical trial
Stock ONCY logo
Oncolytics Biotech, Inc.

Nasdaq:ONCY

ONCY Rankings

#5205 Ranked by Market Cap
#846 Ranked by Stock Gains
N/A Ranked by Dividends

ONCY Stock Data

85.98M
66.96M
6.16%
6.88%
1.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Calgary

About ONCY

oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.